Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Free Cash Flow: 2014-2024

Historic Free Cash Flow for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$32.8 million.

  • Cartesian Therapeutics' Free Cash Flow fell 306.45% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$68.9 million, marking a year-over-year decrease of 42.32%. This contributed to the annual value of -$32.8 million for FY2024, which is 36.21% up from last year.
  • As of FY2024, Cartesian Therapeutics' Free Cash Flow stood at -$32.8 million, which was up 36.21% from -$51.4 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Free Cash Flow registered a high of $34.1 million during FY2020, and its lowest value of -$61.5 million during FY2021.
  • Its 3-year average for Free Cash Flow is -$39.0 million, with a median of -$32.8 million in 2022.
  • Per our database at Business Quant, Cartesian Therapeutics' Free Cash Flow skyrocketed by 166.17% in 2020 and then tumbled by 280.44% in 2021.
  • Over the past 5 years, Cartesian Therapeutics' Free Cash Flow (Yearly) stood at $34.1 million in 2020, then tumbled by 280.44% to -$61.5 million in 2021, then spiked by 46.59% to -$32.8 million in 2022, then slumped by 56.45% to -$51.4 million in 2023, then surged by 36.21% to -$32.8 million in 2024.